Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis
Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis
复制标题
DOI：
10.1182/blood-2005-06-2393
复制
发表时间：
2006-01-01
期刊：
影响因子：
20.3
通讯作者：
Kimura, A
中科院分区：
文献类型：
--
作者：
Mihara, K;Chowdhury, M;Kimura, A
国际预后评分系统（IPSS）已被广泛用于预测骨髓增生异常综合征（MDS）患者的预后。然而，IPSS并不总是提供足够精确的患者评估，以允许适当的临床干预选择。在这里，我们分析了51例MDS和MDS前急性髓系白血病（MDS- aml）患者的CD34（+）细胞中调节自我更新所需的Bmi-1的表达。与难治性贫血（RA）和伴环状铁母细胞（RARS）的RA相比，Bmi-1在伴过量母细胞的难治性贫血（RAEB）、转化型RAEB （RAEB- t）和MDS-AML中阳性率较高。IPSS评分与Bmi-1表达百分比呈正相关。具有较高Bmi-1（+）细胞百分比的RA和RARS患者显示疾病进展为RAEB。在此，我们提出Bmi-1作为一种新的分子标志物来预测MDS的进展和预后。
The International Prognostic Scoring System (IPSS) has been widely used to predict the prognosis of patients with myelodysplastic syndrome (MDS). However, IPSS does not always provide a sufficiently precise evaluation of patients to allow the appropriate choice of clinical interventions. Here, we analyzed the expression of Bmi-1, which is required to regulate the self-renewal in CD34(+) cells from 51 patients with cases of MDS and acute myeloid leukemia preceded by MDS (MDS-AML). Higher positivity rate of Bmi-1 was preferentially seen in refractory anemia with excess blasts (RAEB), RAEB in transformation (RAEB-T), and MDS-AML compared with refractory anemia (RA) and RA with ringed sideroblasts (RARS). IPSS score was positively correlated with the percentage of Bmi-1 expression. Patients with RA and RARS with a higher percentage of Bmi-1(+) cells showed disease progression to RAEB. Here, we propose Bmi-1 as a novel molecular marker to predict the progression and prognosis of MDS.